Eli Lilly gets FDA approval to sell Mounjaro as obesity drug called Zepbound
Eli Lilly’s blockbuster drug tirzepatide, sold as Mounjaro for type 2 diabetes, has been cleared to treat obesity, making it the second in a highly effective class of weight loss medications to enter the market.
The Food and Drug Administration’s long-awaited approval of the drug, which will be marketed under the name Zepbound for obesity, is a major milestone for Lilly. It also introduces stiff competition for Novo Nordisk, which has had to limit starter doses of its obesity treatment Wegovy due to ongoing shortages.
